Which prescription medications are indicated for osteopenia in a postmenopausal woman who is not receiving hormone replacement therapy?

No Prescription Medications Are Indicated for Osteopenia Alone

In a postmenopausal woman with osteopenia (T-score between -1.0 and -2.5) who is not using hormone replacement therapy, prescription medications are generally NOT indicated unless she meets criteria for high fracture risk. The decision to treat osteopenia pharmacologically depends entirely on calculated fracture risk, not the diagnosis of osteopenia itself 1, 2.

Risk Stratification Is Essential

The critical distinction is between osteopenia (low bone mass) and high fracture risk:

• Osteopenia alone does NOT warrant pharmacologic treatment 2
• Treatment should only be considered when 10-year fracture risk reaches specific thresholds:
  • ≥20% risk of major osteoporotic fracture, OR
  • ≥3% risk of hip fracture 2

Use the FRAX® tool or country-specific assessment tools to calculate actual fracture risk 1. This incorporates age, BMI, prior fractures, parental hip fracture history, smoking, glucocorticoid use, and other clinical risk factors beyond just bone density.

When Pharmacologic Treatment IS Indicated

If fracture risk assessment places your patient at high risk despite "only" having osteopenia, then treatment is appropriate 2. The 2023 ACP guidelines specifically address this scenario, recommending an individualized approach for women over 65 with osteopenia 3.

First-Line Options for High-Risk Osteopenia:

Bisphosphonates are the preferred initial therapy if treatment is warranted 2, 4:

• Alendronate 70 mg weekly (oral)
• Risedronate 35 mg weekly (oral)
• Zoledronic acid 5 mg every 2 years (IV) for prevention 2

The evidence for bisphosphonates in osteopenia specifically is limited. The ACP found only very low-certainty evidence that zoledronate may reduce clinical vertebral fractures in this population, with insufficient evidence for hip fractures 3.

Alternative Options:

Raloxifene 60 mg daily may be appropriate for younger postmenopausal women with osteopenia who have 2, 1:

• Low risk of deep vein thrombosis
• High risk of breast cancer (additional benefit)
• Contraindications to bisphosphonates

What IS Universally Recommended

All postmenopausal women with osteopenia should receive non-pharmacologic interventions 1, 2:

• Calcium supplementation: 1,200 mg daily (ages 51-70+) 2
• Vitamin D supplementation: 600-800 IU daily (higher doses if deficient; target serum level ≥20 ng/mL) 2
• Weight-bearing exercise 2
• Smoking cessation 2
• Alcohol moderation 2
• Falls prevention strategies (increasingly important with age) 1

Critical Pitfalls to Avoid

1. Do not prescribe osteoporosis medications based solely on a T-score of -1.0 to -2.5 without fracture risk assessment. This leads to overtreatment of low-risk patients 3.

2. Do not assume all postmenopausal women need pharmacologic treatment. The evidence shows treating osteopenia without high fracture risk is not cost-effective 5.

3. Do not forget to reassess. If you choose observation, repeat DEXA scanning every 2-3 years and recalculate fracture risk, as this changes with age and other factors 2.

4. Do not overlook secondary causes. Before labeling as "primary osteopenia," ensure you've ruled out vitamin D deficiency, hyperparathyroidism, hyperthyroidism, celiac disease, and medication effects (especially glucocorticoids) 2.

The Bottom Line Algorithm

For a postmenopausal woman with osteopenia NOT on HRT:

1. Calculate 10-year fracture risk using FRAX®

2. If fracture risk is LOW (major osteoporotic fracture <20% AND hip fracture <3%):

   • Calcium 1,200 mg daily
   • Vitamin D 600-800 IU daily
   • Lifestyle modifications
   • Repeat DEXA in 2-3 years
   • NO prescription osteoporosis medication

3. If fracture risk is HIGH (major osteoporotic fracture ≥20% OR hip fracture ≥3%):

   • Start bisphosphonate (alendronate or risedronate weekly, or zoledronic acid IV)
   • Continue calcium, vitamin D, and lifestyle measures
   • Consider raloxifene if bisphosphonates contraindicated and breast cancer risk is elevated

The 2019 Endocrine Society guidelines focus on osteoporosis (T-score ≤-2.5), not osteopenia 1. The 2013 ACOG guidelines and 2023 ACP guidelines provide the clearest guidance that osteopenia alone, without elevated fracture risk, does not warrant pharmacologic intervention 2, 3.